Live Breaking News & Updates on Franz Werner Haas

Stay updated with breaking news from Franz werner haas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LimmaTech Biologics Reports Positive Interim Phase I/II Clinical Data on Tetravalent Shigella Bioconjugate Vaccine S4V

SCHLIEREN, Switzerland, February 22, 2024 LimmaTech Biologics AG announced positive interim data from its Phase I/II clinical trial evaluating Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate against shigellosis, an infectious disease caused by Shigella bacteria. Shigellosis is a serious infection and remains the second leading cause of fatal diarrheal disease, particularly in infants in low- and middle-income countries. In the nine-month-old target population, administration of S ....

United Kingdom , Limmatech Biologics , Alexander Siebert , Patricia Martin , Franz Werner Haas , Network Meeting , Trophic Communications , Chief Operating Officer , Annual Network Meeting , Wellcome Trust , Gram Negative Shigella , Tech Biologics , Werner Haas , Clinical Trial , Vaccine Candidate , Diarrheal Disease , Tolerability Profile , Topline Results , Target Population , Clinical Development ,

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million

LimmaTech Biologics Adds Additional $3 Million in Series A Second Closing Bringing Total Raised to $40 Million
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Franz Werner Haas , Paul Wolfrom , Alexander Siebert , Nicola Forrest , Limmatech Biologics , Steve Burnell , Stefan Klotter , Trophic Communications , Impact Fund , Novo Holdings , Adjuvant Capital , Chief Executive Officer , Managing Director , Chief Financial Officer , Tech Biologics , Werner Haas , Die Performance Strategie , Assets Sie ,

LimmaTech Biologics Raises Additional $3M in Series A

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Limmatech Biologics , Franz Werner Haas , Novo Holdings , Impact Fund , Adjuvant Capital ,

LimmaTech, AbVacc sign agreement for S. aureus vaccine candidate

LimmaTech, AbVacc entered into agreement, providing the former with exclusive rights for development of the latter's multivalent toxoid vaccine candidate ....

Franz Werner Haas , National Institutes Of Health , National Institute Of Allergy , National Institute , Infectious Diseases , National Institutes ,

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc's Innovative Vaccine Candidate Against Staphylococcus aureus

LimmaTech Biologics Expands Vaccine Pipeline by Licensing AbVacc's Innovative Vaccine Candidate Against Staphylococcus aureus
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United Kingdom , Gretchen Schweitzer , Javad Aman , Franz Werner Haas , Limmatech Biologics , Michael Kowarik , National Institutes Of Health , Biomedical Advanced Research , Development Authority , Impact Fund , Human Services , National Institute Of Allergy , Us National Institute Of Allergy , Germany Federal Ministry Of Education , Administration For Strategic Preparedness , World Health Organization , Trophic Communications , United Kingdom Global Antimicrobial Resistance Innovation Fund , Us Department Of Health , United Kingdom Government Department Of Health , Abvacc Inc , Novo Holdings , Tech Biologics , Chief Executive Officer , Chief Scientific Officer , National Institutes ,